[Featured Stock] Daewoong Pharmaceutical Rises 4.33% on 'Export Expansion Expectations'

Daewoong Pharmaceutical's stock price is on the rise, expected to perform well due to the expansion of overseas sales of key products.

As of 9:12 AM on the 10th, Daewoong Pharmaceutical was trading at 149,400 KRW, up 6,200 KRW (4.33%) from the previous trading day.

On the same day, researcher Wi Haeju from Korea Investment & Securities said, "We expect continued improvement in gross profit due to increased sales of core products Toxin and Pexuclu," maintaining a buy rating and a target price of 220,000 KRW for Daewoong Pharmaceutical. He stated, "Operating profit for Daewoong Pharmaceutical in the third quarter of this year is expected to exceed the market consensus by 9.6%," adding, "Sales are projected at 321.1 billion KRW and operating profit at 41.7 billion KRW, representing increases of 6.0% and 21.8% respectively compared to the same period last year."

On the same day, researcher Lee Seonkyung from SK Securities maintained a buy rating and a target price of 180,000 KRW, saying, "Despite a solid core business, the company is undervalued compared to peer companies." She forecasted consolidated sales of 351.9 billion KRW and operating profit of 35.6 billion KRW for the third quarter of this year, expecting increases of 3.2% and 21.1% respectively compared to the same period last year, in line with market consensus. She also noted, "The flagship product Nabota has shown steady sales, with its market share in the U.S. increasing from 11% last year to 13% in the second quarter."